503 related articles for article (PubMed ID: 26856846)
21. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients.
Gauthier TP; Wolowich WR; Reddy A; Cano E; Abbo L; Smith LB
Antimicrob Agents Chemother; 2012 May; 56(5):2392-6. PubMed ID: 22371891
[TBL] [Abstract][Full Text] [Related]
22. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium.
Hassan MM; Gaifer Z; Al-Zakwani IS
Int J Clin Pharm; 2018 Apr; 40(2):444-449. PubMed ID: 29542034
[TBL] [Abstract][Full Text] [Related]
23. Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery.
Gomes EC; Falci DR; Bergo P; Zavascki AP; Rigatto MH
Int J Antimicrob Agents; 2018 Jul; 52(1):86-89. PubMed ID: 29501603
[TBL] [Abstract][Full Text] [Related]
24. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.
Phe K; Shields RK; Tverdek FP; Aitken SL; Guervil DJ; Lam WM; Musgrove RJ; Luce AM; Tam VH
J Antimicrob Chemother; 2016 Dec; 71(12):3585-3587. PubMed ID: 27543655
[TBL] [Abstract][Full Text] [Related]
25. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction.
Turkoglu M; Dizbay M; Ciftçi A; Aksakal FN; Aygencel G
Int J Antimicrob Agents; 2012 Feb; 39(2):142-5. PubMed ID: 22115538
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of intravenous colistin in children.
Kumar PP; Giri SR; Shaikh FA; Panigrahy N; Chirla D
Indian Pediatr; 2015 Feb; 52(2):129-30. PubMed ID: 25691180
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
[TBL] [Abstract][Full Text] [Related]
28. Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: A real-world, retrospective cohort study.
Zhang Y; Dong R; Huang Y; Ling X; Ye Z; Jiang S
Int J Antimicrob Agents; 2024 Jan; 63(1):107031. PubMed ID: 37951480
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
Cheng CY; Sheng WH; Wang JT; Chen YC; Chang SC
Int J Antimicrob Agents; 2010 Mar; 35(3):297-300. PubMed ID: 20045293
[TBL] [Abstract][Full Text] [Related]
30. High-dose colistin for microbiologically documented serious respiratory infections associated with carbapenem-resistant Acinetobacter baummannii in critically ill cancer patients: a retrospective cohort study.
Nazer LH; Rihani S; Hawari FI; Le J
Infect Dis (Lond); 2015; 47(11):755-60. PubMed ID: 26050703
[TBL] [Abstract][Full Text] [Related]
31. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.
Dalfino L; Puntillo F; Mosca A; Monno R; Spada ML; Coppolecchia S; Miragliotta G; Bruno F; Brienza N
Clin Infect Dis; 2012 Jun; 54(12):1720-6. PubMed ID: 22423120
[TBL] [Abstract][Full Text] [Related]
32. Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections.
Durante-Mangoni E; Andini R; Signoriello S; Cavezza G; Murino P; Buono S; De Cristofaro M; Taglialatela C; Bassetti M; Malacarne P; Petrosillo N; Corcione A; Viscoli C; Utili R; Gallo C
Clin Microbiol Infect; 2016 Dec; 22(12):984-989. PubMed ID: 27545697
[TBL] [Abstract][Full Text] [Related]
33. Risk Factors for Colistin-Associated Acute Kidney Injury: A Multicenter Study from Turkey.
Gul S; Kuscu F; Aydemir H; Ozturk DB; Deveci O; Duygu F; Kacmaz B; Yaman F; Aslan E
Jpn J Infect Dis; 2016; 69(2):109-12. PubMed ID: 26166495
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.
Sobieszczyk ME; Furuya EY; Hay CM; Pancholi P; Della-Latta P; Hammer SM; Kubin CJ
J Antimicrob Chemother; 2004 Aug; 54(2):566-9. PubMed ID: 15269195
[TBL] [Abstract][Full Text] [Related]
35. Incidence and Risk Factors for Colistin-Associated Nephrotoxicity.
Temocin F; Erdinc S; Tulek N; Demirelli M; Bulut C; Ertem G
Jpn J Infect Dis; 2015; 68(4):318-20. PubMed ID: 25720641
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.
Crusio R; Rao S; Changawala N; Paul V; Tiu C; van Ginkel J; Chapnick E; Kupfer Y
Scand J Infect Dis; 2014 Jan; 46(1):1-8. PubMed ID: 24206450
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and safety of colistin: prospective comparative cohort study.
Paul M; Bishara J; Levcovich A; Chowers M; Goldberg E; Singer P; Lev S; Leon P; Raskin M; Yahav D; Leibovici L
J Antimicrob Chemother; 2010 May; 65(5):1019-27. PubMed ID: 20299494
[TBL] [Abstract][Full Text] [Related]
38. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
Kassamali Z; Danziger L
Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
[TBL] [Abstract][Full Text] [Related]
39. Nephrotoxicity of intravenous colistin: a prospective evaluation.
Falagas ME; Fragoulis KN; Kasiakou SK; Sermaidis GJ; Michalopoulos A
Int J Antimicrob Agents; 2005 Dec; 26(6):504-7. PubMed ID: 16280245
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Renal Toxicity of Colistin Therapy With Neutrophil Gelatinase-associated Lipocalin: a Biomarker of Renal Tubular Damage.
Ordooei Javan A; Salamzadeh J; Shokouhi S; Sahraei Z
Iran J Kidney Dis; 2017 Nov; 11(6):447-455. PubMed ID: 29190605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
